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Background: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate
(eGFR) has been widely integrated into clinical practice. Although useful in screening for CKD, its’ application in
critically ill patients with normal plasma creatinine concentrations remains uncertain. The aim of this study was to
assess the performance of CKD-EPI eGFR in comparison to creatinine clearance (CLCR) in this setting.
Methods: This prospective observational study was performed in a tertiary level, university affiliated intensive care
unit (ICU). Study participants had to have an expected ICU length of stay > 24 hours, a plasma creatinine
concentration < 121 μmol/L, and no history of prior renal replacement therapy or CKD. CKD-EPI eGFR was compared
against 8-hour measured urinary CLCR. Data capture occurred within 48 hours of admission.
Results: One hundred and ten patients (n = 110) were enrolled in the study. 63.6% were male, the mean age was 50.9
(16.9) years, 57.3% received invasive mechanical ventilation, and 30% required vasopressor support. The mean CLCR was
125 (45.1) ml/min/1.73 m2, compared to a CKD-EPI eGFR of 101 (23.7) ml/min/1.73 m2 (P < 0.001). Moderate correlation
was evident (r = 0.72), although there was significant bias and imprecision (24.4 +/− 32.5 ml/min/1.73 m2). In those
patients with a CKD-EPI eGFR between 60–119 ml/min/1.73 m2 (n = 77), 41.6% displayed augmented renal clearance
(CLCR≥ 130 ml/min/1.73 m
2), while 7.8% had a CLCR < 60 ml/min/1.73 m
2.
Conclusions: These data suggest CKD-EPI eGFR and measured CLCR produce significantly disparate results when
estimating renal function in this population. Clinicians should consider carefully which value they employ in clinical
practice, particularly drug dose modification.Background
Accurate assessment of renal function is a priority in the
management of critically ill patients. Clinicians regularly
utilize such information to help guide drug dosing,
optimize fluid, acid–base, and electrolyte management,
tailor nutritional requirements, and assess the need for
renal replacement therapy (RRT). Rising plasma creatinine* Correspondence: andrew_udy@health.qld.gov.au
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reproduction in any medium, provided the or(CR) concentrations often trigger clinical interventions, in-
cluding dose reduction of renally eliminated agents. In
contrast, plasma CR concentrations within the reported
reference range appear to be less useful. Normal values in
the critically ill have been associated with both augmented
creatinine clearance (CLCR) [1], and occult acute kidney
injury (AKI) [2].
Driven primarily by a desire to more effectively monitor
and screen for chronic kidney disease (CKD), formulae
using simple demographic variables have been developed
to estimate the glomerular filtration rate (eGFR). The most
commonly applied include the Modification of Diet in
Renal Disease (MDRD) [3], and newer CKD Epidemiology. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion is based principally on large cohort studies that ef-
fectively stratify patients in terms of long-term clinical
risk [5,6]. This has led to recommendations for wide-
spread laboratory reporting of eGFR [7,8].
While these initiatives represent key developments in
improving the quality of care for patients with CKD,
some clinicians have expressed concern about the ubi-
quitous application of eGFR, particularly in dose modi-
fication [9]. Use of formulae to help guide drug dosing
represents an attractive approach, although an ability to
trigger both dose reduction and escalation is required.
Currently there is a paucity of data examining whether
eGFR could be used in place of conventional measures for
such a purpose, particularly in the critical care environ-
ment. The aim of this study was therefore to compare
CKD-EPI eGFR with measured urinary CLCR, in a cohort




This study was performed in a tertiary level, university
affiliated, metropolitan intensive care unit (ICU), over a
two-month period. Enrolment utilized convenience sam-
pling. Ethical approval was obtained from the institu-
tional Human Research Ethics Committee (HREC/09/
QRBW/192), with written informed consent obtained
from either the patient or their nominated substitute
decision-maker.
Study population
Study participants had to have an anticipated ICU length
of stay (LOS) > 24 hours, a plasma CR concentration <
121 μmol/L, and no history of prior renal replacement
therapy or CKD. Patients were excluded if: a) either inva-
sive haemodynamic monitoring or an indwelling urinary
catheter (IDC) were not employed as part of standard
management; b) they were < 18 years of age; c) they were
pregnant; d) rhabomyolysis was clinically suspected or the
admission plasma creatinine kinase was > 5000 IU/L; or e)
they were in the ‘risk’ category or greater for AKI, as de-
fined by the RIFLE criteria [10]. Patients undergoing an
operative procedure within 24 hours prior to admission
were classified as ‘surgical’. Planned post-operative admis-
sions were considered ‘elective’.
Interventions
Demographic and illness severity characteristics, includ-
ing; age, gender, anthropometric measures, diagnosis, and
acute physiology and chronic health evaluation (APACHE)
II scores were recorded on admission. Modified (excluding
the neurological component) sequential organ failure as-
sessment (SOFA) scores, ventilation parameters, 24-hourfluid balance, vasopressor administration, and diuretic use,
were recorded prospectively at the time of CLCR assess-
ment. ICU and hospital LOS, and ICU mortality were de-
termined for all patients. Data capture occurred within
48 hours of admission to the ICU, as determined by staff
availability and admission time.
An 8-hour measured CLCR was obtained using the
following method. Urine was collected via the IDC be-
tween midnight and 0800 hrs, following which urinary
volume and CR concentration were determined by labora-
tory analysis. Concurrent plasma CR concentrations were
obtained at a point mid-way through the urinary collec-
tion, following which CLCR was calculated using the for-
mula listed below. CR measurement in plasma and urine
utilised automated analysers employing a modified Jaffe
(alkaline picrate) technique, representing an isotope dilu-
tion mass spectrometry (IDMS) traceable assay.
As per convention, CLCR values were normalised to a
body surface area (BSA) of 1.73 m2. The abbreviated 175
MDRD (175 eGFR), CKD-EPI (CKD-EPI eGFR), and
Cockcroft-Gault (CG CLCR) equations were used to calcu-
late estimates for comparison, as outlined below. Aug-
mented renal clearance (ARC) was defined as a measured
8-hr CLCR ≥ 130 ml/min/1.73 m
2, given the association
with sub-therapeutic drug concentrations, when using
standard doses of renally eliminated antibiotics [11,12].
List of equations employed
BSA ¼ 0:007184 ðHtÞ0:725  ðWtÞ0:425
CLCR ¼ UCR  UVol=PCR  480ð Þ  1:73=BSA
CGCLCR ¼ 140‐ageð Þ Wt 1:23 if male; 1:04 if femaleð Þ½ 
=PCR  1:73=BSA
175eGFR ¼ 175 ðPCR  0:0113Þ‐1:154  age‐0:203
0:742 if femaleð Þ
CKD‐EPI eGFR
Females;PCR ≤ 62 ¼ 144 PCR  0:0113=0:7ð Þ‐0:329
0:993 age
Females;PCR > 62 ¼ 144 PCR  0:0113=0:7ð Þ‐1:209
0:993age
Males; PCR ≤ 80 ¼ 141 PCR  0:0113=0:9ð Þ‐0:411  0:993 age
Males; PCR > 80 ¼ 141 PCR  0:0113=0:9ð Þ‐1:209
0:993 age
Where CLCR = 8-hr Creatinine Clearance (ml/min/
1.73 m2), UCR =Urinary Creatinine Concentration (μmol/L),
UVol =Urinary volume (ml), PCR = Plasma Creatinine Con-
centration (μmol/L), BSA =Body Surface Area (m2), Ht =
Height (cm), Wt =Weight (kg), CG CLCR =Cockcroft-Gault
Table 1 Demographic, illness severity and treatment data
Variable N = 110
Age, years, mean (SD) 50.9 (16.9)
Gender, male/female, n (%) 70 (63.6)/40
(36.4)
Height, m, mean (SD) 1.71 (0.09)
Weight, kg, mean (SD) 80.9 (22.4)
Body surface area, m2, mean (SD) 1.92 (0.24)
APACHE II, mean (SD) 16.1 (6.20)
Modified SOFA, median [IQR] 3 [2-5]
Admission type, n (%)
- Elective 15 (13.6)
- Emergency 33 (30.0)
- Surgical emergency 37 (33.6)
- Trauma 25 (22.7)
Mechanical ventilation, n (%) (n = 108) 63 (57.3)
Intravenous contrast administration, n (%) (n = 109) 30 (27.3)
Frusemide administration, n (%) 13 (11.8)
Mannitol administration, n (%) 4 (3.6)
Vasopressors, n (%) 33 (30.0)
Systemic inflammatory response syndrome, n (%) 95 (86.4)
Plasma creatinine concentration, μmol/L, mean (SD) 68.5 (21.8)
Plasma creatinine concentration + 24 hrs, μmol/L, mean
(SD) (n = 80)
63.0 (19.6)
ICU length of stay, days, median [IQR] 4 [2-10]
ICU mortality, n (%) 11 (10)
APACHE-Acute physiology and chronic health evaluation, ICU-Intensive care
unit, SOFA-sequential organ failure assessment.
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viated Modification of Diet in Renal Disease 175 formula
(ml/min/1.73 m2), and, CKD-EPI eGFR =Chronic Kidney
Disease Epidemiology Collaboration Equation (ml/min/
1.73 m2), age (in years).
Statistical analysis
Continuous data are presented as the mean (SD) or me-
dian [IQR] depending on adherence to a normal distribu-
tion. Normality was assessed by visual inspection, and a
one-sample Kolmogorov-Smirnov test. Categorical data are
presented as counts (%). Correlations were assessed using
a Pearson correlation coefficient (r). Precision and bias
were examined using a Bland-Altman plot, with the bias
representing the mean difference between each variable,
and precision being one SD from the mean. Comparison
of continuous data utilized a paired Students T-test. A two-
sided P-value < 0.05 was considered as statistical signifi-
cance, and all analyses were performed using SPSS version
21 (IBM Corporation, Armonk, New York) and PRISM
version 5 (GraphPad Software Inc, La Jolla, California).
Results
One hundred and ten patients (n = 110) were enrolled in
the study, with all participants completing an 8-hr CLCR.
Demographic, admission, illness severity and outcome
data are presented in Table 1. As illustrated, approximately
two-thirds of the cohort was male, the patients were rela-
tively young (50.9 (16.9) years), greater than 50% received
invasive mechanical ventilation, and about one-third re-
quired vasopressor support. Less than 15% were elective
cases, with the majority manifesting systemic inflamma-
tion, with or without undergoing prior surgery. As per
protocol, plasma CR concentrations were within the nor-
mal reference range (68.5 (21.8) μmol/L), and did not
change significantly in the following 24 hrs (P = 0.157),
where data were available. The mean 8-hr CLCR was 125
(45.1) ml/min/1.73 m2, 48.2% (n = 53) manifested ARC,
and 10 (9.1%) had a CLCR < 60 ml/min/1.73 m
2.
A comparison of measured 8-hr CLCR and 175 eGFR,
CG CLCR, and CKD-EPI eGFR in all patients, and each
diagnostic category separately, are presented in Table 2.
Scatter graphs using all data points are provided in Figure 1.
Equivalent Bland-Altman plots are presented in Figure 2.
Across all groups, the observed bias is greatest with the
CKD-EPI equation. A significant proportional error is also
apparent, with higher average values significantly correlated
with a larger positive bias (Figure 2C, r = 0.705, P < 0.001).
This was not evident with either the 175 eGFR (r = 0.102,
P = 0.289), or CG CLCR (r = 0.103, P = 0.285) formulae.
8-hr CLCR values were used to categorize patients into
four groups; < 90, 90–119, 120–149, and ≥ 150 ml/min/
1.73 m2. Comparisons with each mathematical estimate
are presented in Table 3 and Figure 3. As illustrated, CKD-EPI eGFR was generally higher than CLCR in the lower
range (< 90 ml/min/1.73 m2), although the opposite was
observed at higher values. Correlation was generally poor
in each group (Table 3). In those patients with a calculated
CKD-EPI eGFR between 60–119 ml/min/1.73 m2 (n = 77),
8-hr CLCR values were significantly higher (118 (38.3) vs 96
(16.6) ml/min/1.73 m2, P < 0.001), 41.6% (n = 32) displayed
ARC, and 7.8% (n = 6) had a CLCR < 60 ml/min/1.73 m
2.Discussion
To our knowledge, this is the first report of CKD-EPI eGFR
performance in a cohort of Australian patients recently ad-
mitted to the ICU. These data demonstrate significant dis-
parity between CKD-EPI eGFR and measured CLCR in
patients with normal plasma CR concentrations. Despite
an overall reasonable correlation, bias and precision were
unacceptable across a range of values. This highlights that
clinicians must carefully consider which estimate of renal
function they use in clinical decision-making, as these may
be very dissimilar. A modest fraction of study participants
Table 2 Comparison, correlation, bias and precision
between measured 8-hr CLCR and mathematical estimates
in all patients, and each diagnostic sub-group
Mean
(SD)
r (P-value) Bias +/−
precision























115 (51.2) 0.325 (0.237) 2.77 +/− 49.5
CG CLCR, ml/min/
1.73 m2





0.488 (0.065) 17.2 +/− 24.7


























































* P < 0.001, when compared to CLCR ** P < 0.05, when compared to CLCR.
CLCR = 8-hr Creatinine Clearance, CG CLCR = Cockcroft-Gault Creatinine
Clearance, 175 eGFR = Abbreviated Modification of Diet in Renal Disease 175
formula, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration
Equation, r = Pearson correlation coefficient.
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Figure 1 Scatter graphs of CLCR versus mathematical estimates in
all patients. CLCR on the x-axis compared with 175 eGFR (panel A), CG
CLCR (panel B), and CKD-EPI eGFR (panel C), on the y-axis. CLCR = 8-hr
Creatinine Clearance, 175 eGFR = Abbreviated Modification of Diet
in Renal Disease 175 formula, CG CLCR = Cockcroft-Gault Creatinine
Clearance, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology
Collaboration Equation.
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be expected, a finding that requires further evaluation.
Albeit the CKD-EPI equation is relatively new in
Australian practice, ours is not the only study to explorethe use of eGFR formulae in the critically ill. Martin and
colleagues examined the utility of MDRD eGFR and CG
CLCR in comparison to 8-hr CLCR in a cohort of mainly
traumatised patients [13]. CLCR measures were markedly











































































Figure 2 Bland-Altman plots of CLCR versus mathematical
estimates in all patients. Comparison of the difference between CLCR
and 175 eGFR (panel A), CG CLCR (panel B), and CKD-EPI eGFR (panel
C) on the y-axis, versus the average value obtained on the x-axis. CLCR
= 8-hr Creatinine Clearance, 175 eGFR = Abbreviated Modification of
Diet in Renal Disease 175 formula, CG CLCR = Cockcroft-Gault Creatinine
Clearance, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology
Collaboration Equation.
Table 3 Correlation, bias and precision across different
ranges of CLCR
r (P-value) Bias +/− precision
(ml/min/1.73 m2)
CLCR < 90 ml/min/1.73 m
2 (n = 28)
175 eGFR 0.223 (0.253) −12.6 +/− 35.2
CG CLCR 0.278 (0.152) −15.9 +/− 37.2
CKD-EPI eGFR 0.351 (0.067) −11.1 +/− 23.2
CLCR 90–119 ml/min/1.73 m
2 (n = 23)
175 eGFR 0.065 (0.767) 10.5 +/− 44.4
CG CLCR 0.066 (0.763) −0.93 +/− 43.9
CKD-EPI eGFR −0.067 (0.760) 14.8 +/− 22.8
CLCR 120–149 ml/min/1.73 m
2 (n = 23)
175 eGFR 0.047 (0.832) 22.7 +/− 26.1
CG CLCR 0.369 (0.083) 6.62 +/− 23.9
CKD-EPI eGFR 0.347 (0.104) 29.2 +/− 10.8
CLCR≥ 150 ml/min/1.73 m
2 (n = 36)
175 eGFR 0.427 (0.009) 36.1 +/− 31.3
CG CLCR 0.399 (0.016) 27.8 +/− 27.2
CKD-EPI eGFR 0.460 (0.005) 55.0 +/− 20.9
CLCR = 8-hr Creatinine Clearance, CG CLCR = Cockcroft-Gault Creatinine
Clearance, 175 eGFR = Abbreviated Modification of Diet in Renal Disease 175
formula, CKD-EPI eGFR = Chronic Kidney Disease Epidemiology Collaboration















































































Figure 3 Comparison of CLCR with mathematical estimates over
different ranges. CLCR compared with 175 eGFR, CG CLCR, and
CKD-EPI eGFR over different ranges. CLCR < 90 (open), 90–119 (solid),
120–149 (lines), and≥ 150 (dots) ml/min/1.73 m2. * P < 0.05, ** P <
0.001. CLCR = 8-hr Creatinine Clearance, 175 eGFR = Abbreviated
Modification of Diet in Renal Disease 175 formula, CG CLCR = Cock-
croft-Gault Creatinine Clearance, CKD-EPI eGFR = Chronic Kidney Dis-
ease Epidemiology Collaboration Equation.
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tions. In ~350 recently admitted patients, Herrera-
Gutierrez et al. demonstrated significant bias when com-
paring CG CLCR to measured values [14]. This was
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100 ml/min/1.73 m2), where CG estimates were markedly
lower. Other studies in surgical intensive care [15], and
burns injury [16], have reported similar observations.
Hoste and colleagues examined the relationship between
1-hr CLCR, CG CLCR, and MDRD eGFR in twenty-eight
adult patients recently admitted to the ICU [2]. Here, 25%
had a 1-hr CLCR < 60 ml/min/1.73 m
2, despite a normal
plasma CR concentration. Even with a lower range of
CLCR measures, neither equation was considered specific
enough for clinical use [2]. In our study, fewer patients
manifest this level of renal impairment (n = 10, 9.1%), lim-
iting any definitive conclusions. However, these patients
often (n = 6, 60%) had a normal or near-normal calculated
CKD-EPI eGFR (60–119 ml/min/1.73 m2).
Baptista and colleagues were the first to explore the role
of eGFR in the setting of ARC, comparing CG CLCR and
MDRD eGFR with measured CLCR in eighty-six critically
ill patients [17]. Calculated values were significantly less
than measured CLCR, with considerable bias and impreci-
sion. In a retrospective analysis of 390 patients with ARC
admitted to a single center, Grootaert and colleagues simi-
larly reported poor agreement between CG CLCR, MDRD
eGFR and 24-hr measured CLCR [18].
Confounding these analyses however, is often the lack of
an exogenous marker of GFR. Despite this, markedly ele-
vated renal drug elimination has been noted in many sub-
groups of critically ill patients [19], in parallel with higher
CLCR [20]. Furthermore, recent research suggests elevated
CLCR measures (> 130 ml/min/1.73 m
2) are associated
with sub-therapeutic drug concentrations [11,12] and
worse clinical outcomes [21], in critically ill patients re-
ceiving antimicrobial therapy. While the implications of
this phenomenon require substantial validation, the obs-
ervation that ~40% of patients with a normal or near-
normal CKD-EPI eGFR (60–119 ml/min/1.73 m2) actually
manifest ARC, suggests such thresholds are not simply
transferrable to different estimates of renal function.
This realization is consistent with these formulae being
developed outside of an ICU environment; generating re-
sults that fail to consider the unique characteristics of crit-
ical illness [22,23]. Of note, bias appeared to be greatest in
emergent surgical and trauma admissions (Table 1),
sub-groups where ARC has been previously well do-
cumented [24,25]. Recent data from Shimamoto et al.
suggests systemic inflammation is a key factor, with in-
creasing SIRS criteria associated with elevated renal vanco-
mycin clearance [26]. This has important ramifications for
clinical practice, where use of variable estimates of renal
function may result in disparate conclusions [27,28], po-
tentially leading to inadequate drug dosing [29].
We wish to acknowledge the following limitations.
This paper reports the findings from a single-center
only, and therefore may not be representative of case-mix at other institutions. Despite this, the majority of
study participants manifested a systemic inflammatory
response; over half received invasive mechanical ventila-
tion; and 30% required vasoactive support. Illness sever-
ity scores were moderate, and consistent with tertiary
level ICU practice. Our inclusion criteria were designed
to select a cohort of patients with normal plasma CR
concentrations, as assessing renal function in the con-
text of drug dosing remains challenging in this group.
In addition, the CKD-EPI equation is reported to have
improved accuracy compared to older eGFR estimates
[30], particularly in patients with normal or near-
normal renal function [31].
We have employed 8-hr urinary collections, as recom-
mended by prior research [15]. This method is not a
gold standard measure of GFR, such that tubular CR se-
cretion, and errors in measurement may have con-
founded our results. Without employing an exogenous
filtration maker (such as inulin), it is impossible to de-
termine which estimate is closer to the ‘true’ filtration
rate. As such, use of endogenous CLCR may have re-
sulted in systematically higher values. Despite this, CLCR
remains a common modifier of drug dosing in clinical
practice, with recent data suggesting important pharma-
cokinetic [11,12], and clinical [21] implications. Unfortu-
nately no readily accessible, pragmatic, error free
measure of GFR is currently available. This analysis prin-
cipally serves to remind the clinician of the inherent dis-
crepancy between estimates of GFR in the ICU.Conclusion
In conclusion, this study has examined CKD-EPI eGFR
in comparison to 8-hr measured CLCR in a cohort of re-
cently admitted critically ill patients with normal plasma
CR concentrations. Our results suggest poor agreement
between these techniques in this population. Whether
this represents a true limitation of CKD-EPI eGFR, or
an intuitive discrepancy based on the problems with en-
dogenous CLCR, remains uncertain. Notwithstanding
this, until additional data are available on the utility of
CKD-EPI eGFR for drug dose adjustment, particularly in
identifying ARC, we would recommend clinicians con-
sider using CLCR for this purpose.Abbreviations
AKI: Acute kidney injury; APACHE: Acute physiology and chronic health
evaluation; ARC: Augmented renal clearance; CG CLCR: Cockcroft-Gault
creatinine clearance; CKD: Chronic kidney disease; CKD-EPI: Chronic Kidney
disease epidemiology collaboration; CLCR: Creatinine clearance;
eGFR: Estimated glomerular filtration rate; ICU: Intensive care unit;
IDC: Indwelling urinary catheter; IDMS: Isotope dilution mass spectrometry;
IQR: Inter-quartile range; LOS: Length of stay; MDRD: Modification of diet in
renal disease; RIFLE: Risk, injury, failure, loss, end-stage; RRT: Renal
replacement therapy; SD: Standard deviation; SOFA: Sequential organ failure
assessment.
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